@misc{oai:kawasakigakuen.repo.nii.ac.jp:00000306,
 author = {Naotaka SHINFUKU and Masatoshi TAKEDA},
 month = {Dec},
 note = {Recently, there has been an increased attention paid to the role of Plasmalogens (Pls) to the development of Alzheimer's Disease (AD). Pls are a kind of phospholipids and widely distributed in animal tissues (cell membranes). Pls account for about 18% of the total phospholipids in human, especially abundant in brain, heart, skeletal muscles, leukocytes, and sperms. Growing attention is now focused on the correlation between Pls and AD in the areas of biochemistry, physiology, and brain pathology. A 1995 report paved the way for subsequent studies, showing that Pls is decreased in postmortem brain of patients with AD. Another study has revealed a decrease in blood Pls. Some studies showed that oral administration of Pls improves cognitive function in AD animal models and inhibit amyloid-β accumulation. A multicenter double-blind randomized placebo-controlled trial (DB-RCT) was conducted in patients with mild cognitive impairment (MCI) and mild AD in Japan from 2014 to 2016. This review describes the progress of fundamental and clinical research on the correlation between Pls and AD. The review of these research also brings us to propose a new hypothesis to better understand the etiology of AD., Review Article},
 title = {Neuroinflammation and a plasmalogen hypothesis of Alzheimer’s disease},
 year = {2020}
}